MedTrace Logo

Effect of Different Dosages of Paraxanthine, the Major Caffeine Metabolite, on Energy and Focus

NCT06117280 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2023-11-07

No results posted yet for this study

Summary

Research has shown that acute ingestion of Paraxanthine (1,7-dimethylxanthine, PXN) can enhance various markers of focus, including memory, reaction time, and attention in healthy adults. To assess these effects, this placebo-controlled crossover trial will compare the effects of 200 and 300mg of PXN to a placebo control. Participants will abstain from caffeine for 3 days, before taking the first test/placebo product for 3 consecutive days. Participants will complete questionnaires at 30, 60, 90, and 120 minutes after ingestion on Day 1 and Day 3 of ingestion. Participants will have a 3-day washout period before trialing the next test product/placebo.

Conditions

  • Energy
  • Focus
  • Caffeine Withdrawal

Interventions

OTHER

Paraxanthine 200 mg

For the three-day test cycle, participants will take one capsule per day amounting to 200mg of paraxanthine.

OTHER

Paraxanthine 300 mg

For the three-day test cycle, participants will take one capsule per day amounting to 300mg of paraxanthine.

OTHER

Placebo

The placebo will contain resistant dextrin. For the three-day test cycle, participants will take one capsule per day amounting to 300mg of resistant dextrin.

Sponsors & Collaborators

  • Citruslabs

    collaborator INDUSTRY

  • Iovate Health Sciences International Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-18
Primary Completion
2023-10-18
Completion
2023-10-20

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06117280 on ClinicalTrials.gov